Merrick Ross

Merrick Ross is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in surgical oncology and melanoma research. His work integrates cancer immunotherapy, dermatology, and radiation oncology, focusing on neoadjuvant and adjuvant treatment strategies for resectable and metastatic melanoma. Recent breakthroughs include trials evaluating relatlimab (anti-LAG3) combined with nivolumab (anti-PD1), tumor-infiltrating lymphocyte therapy with IL-2, and pembrolizumab in stage II disease. He has also investigated biomarkers such as CTC PD-L1 expression and conducted international surveys on index lymph node surgery post-neoadjuvant therapy. His publications appear in the Journal of Clinical Oncology, Nature Communications, and Annals of Surgical Oncology, reflecting extensive global collaborations in cancer care and immunology.